This funding opportunity supports projects developing, validating, or evaluating early cancer diagnostic technologies and devices. It prioritizes innovations that enable earlier detection, particularly for less common cancers, and aims to generate evidence for regulatory approval and NHS adoption. Projects must be collaborative, UK-based, and demonstrate clear clinical and health economic impact potential.
Eligible applicants include UK-registered businesses, academic institutions, and NHS organizations leading collaborative projects with at least one UK SME and clinical involvement. Projects must be UK-based with costs between £1.5M and £4M, lasting 24-36 months, starting by April 2027.
